1nkemia IUCT Group SA
MAD:IKM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
1nkemia IUCT Group SA
Net Income (Common)
1nkemia IUCT Group SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
1nkemia IUCT Group SA
MAD:IKM
|
Net Income (Common)
-€506.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Grifols SA
MAD:GRF
|
Net Income (Common)
€402m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Net Income (Common)
-€2.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-10%
|
|
|
Pharma Mar SA
MAD:PHM
|
Net Income (Common)
€75m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
28%
|
|
1nkemia IUCT Group SA
Glance View
1nKemia IUCT Group SA engages in the research and development activities related to pharmaceutical, chemical, and biotechnology industries. The company is headquartered in Mollet Del Valles, Barcelona. The company went IPO on 2012-12-21. The firm provides products and services for chemical, pharmaceutical, biopharmaceutical, life science and related industry. The Company’s activity is related to the generation, promotion, development and sale of products and services. The firm transforms its knowledge and know-how into a pipeline of products, processes, services and technological platforms. Its solutions are specialized, integrated and protected by patents. The main areas of expertise are related to drugs development, industrial biotechnology and green chemistry. The firm has a number of subsidiaries, including IUCT SA and IUCT Empren SL.
See Also
What is 1nkemia IUCT Group SA's Net Income (Common)?
Net Income (Common)
-506.1k
EUR
Based on the financial report for Dec 31, 2022, 1nkemia IUCT Group SA's Net Income (Common) amounts to -506.1k EUR.
What is 1nkemia IUCT Group SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
6%
Over the last year, the Net Income (Common) growth was -346%.
